{"count": 2, "results": [{"_id": "20065889", "pmid": 20065889, "title": "Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.", "journal": "Pharmacogenet Genomics", "authors": ["Nordestgaard BG", "Kontula K", "Benn M", "Dahlöf B", "de Faire U", "Edelman JM", "Eliasson E", "Fyhrquist F", "Hille DA", "Ibsen H", "Lyle PA", "Berg K", "Sandberg M", "Sethi AA", "Wong PH", "Os I"], "date": "2010-02-01T00:00:00Z", "doi": "10.1097/FPC.0b013e328333f70b", "meta_date_publication": "2010 Feb", "meta_volume": "20", "meta_issue": "2", "meta_pages": "77-85", "score": 50063.258, "text_hl": "CONCLUSION: @GENE_ACE @GENE_1636 @@@ACE@@@ insertion/deletion and 12 other polymorphisms of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ susceptibility genes did not affect @DISEASE_Hypotension @DISEASE_MESH:D007022 @@@blood pressure reduction@@@, heart @<m>DISEASE_Xeroderma_pigmentosum_variant_type</m> @DISEASE_MESH:C536766 @@@rate reduction@@@, or cardiovascular events in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @DISEASE_Hypertrophy_Left_Ventricular @DISEASE_MESH:D017379 @@@LVH@@@, or treatment differences between @CHEMICAL_Losartan @CHEMICAL_MESH:D019808 @@@losartan@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ on these endpoints. ", "citations": {"NLM": "Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics. 2010 Feb;20(2):77-85. PMID: 20065889", "BibTeX": "@article{20065889, title={Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.}, author={Nordestgaard BG and Kontula K and Benn M and Dahlöf B and de Faire U and Edelman JM and Eliasson E and Fyhrquist F and Hille DA and Ibsen H and Lyle PA and Berg K and Sandberg M and Sethi AA and Wong PH and Os I}, journal={Pharmacogenet Genomics}, volume={20}, number={2}, pages={77-85}}"}}, {"_id": "6111212", "pmid": 6111212, "title": "Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris.", "journal": "Am Heart J", "authors": ["Schwartz JB", "Jackson G", "Kates RE", "Harrison DC"], "date": "1981-04-01T00:00:00Z", "doi": "10.1016/0002-8703(81)90125-3", "meta_date_publication": "1981 Apr", "meta_volume": "101", "meta_issue": "4", "meta_pages": "380-5", "score": 50063.06, "text_hl": "Treadmill exercise test (ET) were performed at times at peak and trough serum @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ concentrations and 24-hour ECG ambulatory recordings were obtained after placebo, after 2 weeks of 100 and 200 mg @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, and after 2 weeks of 100 and 200 mg @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, and after 3, 6, 9, and 12 months of 100 or 200 mg @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Schwartz JB, Jackson G, Kates RE, Harrison DC. Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris. Am Heart J. 1981 Apr;101(4):380-5. PMID: 6111212", "BibTeX": "@article{6111212, title={Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris.}, author={Schwartz JB and Jackson G and Kates RE and Harrison DC}, journal={Am Heart J}, volume={101}, number={4}, pages={380-5}}"}}]}